Léčebné možnosti u multicentrické Castlemanovy choroby

Title in English Treatment options for multicentric Castleman disease


Year of publication 2013
Type Article in Periodical
Magazine / Source Onkologie
MU Faculty or unit

Faculty of Medicine

Field Oncology and hematology
Keywords Castleman disease; tocilizumab; rituximab; immunomodulatory drugs; thalidomide; lenalidomide
Description Backgrounds: Castleman disease is a rare nonclonal lymphoproliferative disorder with 2 clinical (unicentric and multicentric) and 4 histomorphologic (hyaline-vascular, plasma-cell, mixed and plasmablastic) types. Typically, multicentric plasma-cell Castleman disease is an aggressive, relapsing disorder with generalized lymphadenopathy and systemic symptoms. Due to absence of randomised comparison studies, treatment recommendations for this disease form are not united and mostly, the practicing physicians take guidance from retrospective reports of single cases and small groups of patients. Aim: This paper summarizes the available treatment modalities for multicentric Castleman disease and based on an analysis of literature sources it provides current recommendations for treating the disease. Conclusions: The pillars for treating multicentric Castleman disease should comprise preparates from the groups of monoclonal antibodies(tocilizumab, rituximab) and immunomodulatory drugs (thalidomide, lenalidomide). Positive aspects of thalidomide include favourable financial calculation, the possiblity of long-term administration with lasting therapy effects and reported efficacy in rituximab-resistant cases.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info